Nanjing Leads Biolabs Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2012-11-27
- Employees
- 1
- Market Cap
- -
- Website
- http://leadsbiolabs.com
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
- Conditions
- Advanced Solid Tumour
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06783647
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳Mianyang Central Hospital, Mianyang, Sichuan, China
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
- Conditions
- Advanced Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 178
- Registration Number
- NCT06157827
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
🇨🇳Shanxi Cancer hospital, Taiyuan, Shanxi, China
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Drug: LBL-034 for Injection
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT06049290
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shengyang, Liaoning, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: LBL-033 for Injection
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 468
- Registration Number
- NCT05779163
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
- Conditions
- Malignant Tumors
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 490
- Registration Number
- NCT05516914
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital，Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Huizhou Municipal Central Hospital, Huizhou, Guangdong, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: LBL-019 InjectionDrug: anti-PD-1 antibody injection
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 486
- Registration Number
- NCT05223231
- Locations
- 🇨🇳
Union hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 396
- Registration Number
- NCT05170958
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Anyang Tumor Hospital, Anyang, Henan, China
Phase I/II Clinical Trial of LBL-015 for Injection
- Conditions
- Advanced Malignant Tumor
- Interventions
- Drug: LBL-015 for Injections
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT05107011
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: LBL-007 Injection
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT05102006
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Wuhan Union Hospital of china, Wuhan, Hubei, China
🇨🇳Affiliated Hospital of Jining Medical University, Jining, Shandong, China
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT05042908
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Shangdong Cancer Hospital, Jinan, Shandong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China